20S Proteasome β2 CRISPR/Cas9 KO Plasmid (h): sc-403536

Overview

PSMB2 encodes the β2 catalytic subunit of the human 20S proteasome core particle, a central component of the ubiquitin–proteasome system that governs ATP-dependent protein turnover and antigen processing. As part of the 26S proteasome, 20S β2 contributes to proteolytic cleavage of polyubiquitinated substrates, shaping proteostasis, cell-cycle progression, stress responses, and signaling pathways such as NF-κB through regulated degradation of key regulators. Proteasome activity influences immune surveillance by generating peptides for MHC class I presentation and affects the stability of proteins involved in DNA damage and apoptosis pathways. Dysregulated proteasome function and altered proteasome subunit expression have been implicated in cancer biology, inflammatory signaling, and neurodegenerative protein-aggregation phenotypes, making PSMB2 a useful target for mechanistic studies of proteostasis and cellular adaptation.

20S Proteasome β2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PSMB2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PSMB2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PSMB2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish 20S Proteasome β2 protein expression.

This CRISPR knockout system enables efficient generation of PSMB2-deficient cell models for investigation of 20S Proteasome β2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting PSMB2 exon(s) critical for 20S Proteasome β2 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple PSMB2 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by 20S Proteasome β2 CRISPR/Cas9 KO Plasmid (h) and 20S Proteasome β2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PSMB2 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by 20S Proteasome β2 HDR Plasmid (h) and 20S Proteasome β2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PSMB2 homology arms to support homology-directed repair at defined PSMB2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.